9
Participants
Start Date
July 9, 2013
Primary Completion Date
June 6, 2017
Study Completion Date
June 6, 2017
NYESO-1c259 T cells
Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
Roswell Park Cancer Institute, Buffalo
University of Miami, Sylvester Comprehensive Cancer Center, Miami
MD Anderson Cancer Center, Houston
City of Hope National Medical Center, Duarte
Stanford Cancer Institute, Stanford
Lead Sponsor
Adaptimmune
INDUSTRY